美康生物(300439.SZ)終止公開發行可轉債事項並撤回申請文件
格隆匯12月3日丨美康生物(300439.SZ)公佈,公司於2019年12月3日召開了第三屆董事會第二十二次會議及第三屆監事會第十九次會議,會議審議通過了《關於終止公司公開發行可轉換公司債券事項並撤回申請文件的議案》,同意公司終止公開發行可轉換公司債券事項並向中國證監會申請撤回相關申請文件。
之前公告披露,公司擬公開發行總額不超過人民幣7.3億元可轉換公司債券。
自公司申請此次可轉債以來,公司董事會、經營管理層會同中介機構一直積極有序推進此次可轉債的相關工作。經綜合考慮市場環境、融資政策的變化及公司目前的經營情況等因素後,公司與中介機構經審慎研究決策後,決定終止此次可轉債事宜,並向中國證監會申請撤回相關申請文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.